Prevalence and factors influencing medication adherence after acute myocardial infarction: a systematic review and meta-analysis
6 affiliations
- 1School of Nursing, Hainan Medical University, Haikou, 571199 Hainan China
- 2Key Laboratory of Emergency and Trauma of Ministry of Education, The First Affiliated Hospital of Hainan Medical University, Haikou, 571199 Hainan China
- 3School of Pediatrics, Hainan Medical University, Haikou, 571199 Hainan China
- 4UWE College, Hainan Medical University, Haikou, 571199 Hainan China
- 5Department of Nursing, The First Affiliated Hospital of Hainan Medical University, Haikou, 571199 Hainan China
- 6Hainan Health Vocational College, Haikou, 570311 Hainan China
Abstract
Introduction: Adherence to evidence-based secondary prevention medications is important for long-term management after acute myocardial infarction (AMI). Previous reviews have examined medication adherence and related factors but remain limited by heterogeneity in adherence measures and reliance primarily on narrative synthesis.
Aim: We aimed to estimate the pooled prevalence of objectively measured medication adherence and identify associated factors after AMI.
Method: Five databases (PubMed, Embase, Cochrane Library, Web of Science, and Ovid MEDLINE) were searched from January 1, 2000, to October 5, 2025. Observational studies using objective measures of medication adherence after AMI were included. Random-effects models were used to pool adherence prevalence estimates and adjusted odds ratios (ORs) for associated factors. Heterogeneity was explored through subgroup analyses by adherence measure, follow-up period, and geographical region. Robustness was assessed using leave-one-out sensitivity analyses.
Results: We included 18 retrospective cohort studies involving 680,966 participants from eight countries. The pooled prevalence of adherence was 64.9% (95% CI 56.1–73.8%) for statins, 58.9% (95% CI 49.3–68.4%) for beta‑blockers, 56.7% (95% CI 45.3–68.0%) for P2Y12 inhibitors, 61.3% (95% CI 50.8–71.9%) for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), and 41.4% (95% CI 27.2–55.6%) for multiple-drug therapy (≥ 2 classes). Substantial heterogeneity remained within subgroups. Factors associated with higher adherence included hypertension (OR = 1.39, 95% CI 1.17–1.65), prior cardiovascular medication use (before the index admission for AMI; statins: OR = 1.33, 95% CI 1.15–1.54; beta-blockers: OR = 1.62, 95% CI 1.49–1.75; ACEI/ARB: OR = 1.77, 95% CI 1.65–1.89), ST-segment elevation myocardial infarction (OR = 1.23, 95% CI 1.02–1.48), percutaneous coronary intervention (OR = 2.16, 95% CI 1.34–3.46), and discharge from a cardiology ward (OR = 1.57, 95% CI 1.37–1.80). Factors associated with lower adherence included female sex (OR = 0.78, 95% CI 0.74–0.84), age ≥85 years (OR = 0.48, 95% CI 0.38–0.60), and chronic obstructive pulmonary disease (COPD; OR = 0.78, 95% CI 0.72–0.84).
Conclusion: Medication adherence after AMI was suboptimal and associated with several factors. These findings may inform targeted monitoring and support but require further confirmation given substantial heterogeneity.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11096-026-02224-x.
Related
- Prevalence, causes, and predictors of 30-day readmissions after acute myocardial infarction with ventricular arrhythmias: a cohort study using the 2016–2017 national readmissions database
- Prevalence and Clinical Characteristics of Myocardial Infarction With Non-obstructive Coronary Arteries Compared With Obstructive Myocardial Infarction: A Retrospective Tertiary-Centre Study.
- Angiographic prevalence of occlusion myocardial infarction and the limited value of serial troponin in patients with non-ST-segment elevation acute coronary syndrome.
- Risk of myocardial infarction in adults with gout treated with allopurinol: A systematic review and meta-analysis
- Prevalence and factors influencing influenza vaccination among health care workers in China: a systematic review and meta-analysis.
BibTeX
@article{liao2026prevalence,
title = {{Prevalence and factors influencing medication adherence after acute myocardial infarction: a systematic review and meta-analysis}},
author = {Ruolan Liao and Shihan Zhang and Qi Zhou and Jingyang Wang and Mengzhen Huang and Danxin Wang and Hua Zhang},
journal = {International Journal of Clinical Pharmacy},
year = {2026},
month = sep,
doi = {10.1007/s11096-026-02224-x},
url = {https://doi.org/10.1007/s11096-026-02224-x},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Prevalence and factors influencing medication adherence after acute myocardial infarction: a systematic review and meta-analysis
AU - Ruolan Liao
AU - Shihan Zhang
AU - Qi Zhou
AU - Jingyang Wang
AU - Mengzhen Huang
AU - Danxin Wang
AU - Hua Zhang
PY - 2026
DA - 2026/09/12
JO - International Journal of Clinical Pharmacy
DO - 10.1007/s11096-026-02224-x
UR - https://doi.org/10.1007/s11096-026-02224-x
AB - Introduction: Adherence to evidence-based secondary prevention medications is important for long-term management after acute myocardial infarction (AMI). Previous reviews have examined medication adherence and related factors but remain limited by heterogeneity in adherence measures and reliance primarily on narrative synthesis. Aim: We aimed to estimate the pooled prevalence of objectively measured medication adherence and identify associated factors after AMI. Method: Five databases (PubMed, Embase, Cochrane Library, Web of Science, and Ovid MEDLINE) were searched from January 1, 2000, to October 5, 2025. Observational studies using objective measures of medication adherence after AMI were included. Random-effects models were used to pool adherence prevalence estimates and adjusted odds ratios (ORs) for associated factors. Heterogeneity was explored through subgroup analyses by adherence measure, follow-up period, and geographical region. Robustness was assessed using leave-one-out sensitivity analyses. Results: We included 18 retrospective cohort studies involving 680,966 participants from eight countries. The pooled prevalence of adherence was 64.9% (95% CI 56.1–73.8%) for statins, 58.9% (95% CI 49.3–68.4%) for beta‑blockers, 56.7% (95% CI 45.3–68.0%) for P2Y12 inhibitors, 61.3% (95% CI 50.8–71.9%) for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), and 41.4% (95% CI 27.2–55.6%) for multiple-drug therapy (≥ 2 classes). Substantial heterogeneity remained within subgroups. Factors associated with higher adherence included hypertension (OR = 1.39, 95% CI 1.17–1.65), prior cardiovascular medication use (before the index admission for AMI; statins: OR = 1.33, 95% CI 1.15–1.54; beta-blockers: OR = 1.62, 95% CI 1.49–1.75; ACEI/ARB: OR = 1.77, 95% CI 1.65–1.89), ST-segment elevation myocardial infarction (OR = 1.23, 95% CI 1.02–1.48), percutaneous coronary intervention (OR = 2.16, 95% CI 1.34–3.46), and discharge from a cardiology ward (OR = 1.57, 95% CI 1.37–1.80). Factors associated with lower adherence included female sex (OR = 0.78, 95% CI 0.74–0.84), age ≥85 years (OR = 0.48, 95% CI 0.38–0.60), and chronic obstructive pulmonary disease (COPD; OR = 0.78, 95% CI 0.72–0.84). Conclusion: Medication adherence after AMI was suboptimal and associated with several factors. These findings may inform targeted monitoring and support but require further confirmation given substantial heterogeneity. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11096-026-02224-x.
SN - 2210-7703
SN - 2210-7711
ER -